GLOBE LIFE INC. (GL) Stock News

Establishing industry leading fee-based adjusted EBITDA per share 1 growth targets to 2029 Initial $100 million near-term synergy target substantially realized and target increased Expanded Marketing segment is a strategic competitive advantage; providing 2026 Marketing segment realized margin 1 guidance Capital allocation priorities unchanged; updating 2026 guidance CALGARY, AB , June 15, 2026 /CNW/ - Keyera Corp. (TSX: KEY ) ("Keyera" or the "company") today announced a pro forma business update and multi-year growth outlook following the completion of its transformative acquisition of Plains' Canadian NGL assets. "This combination strengthened Keyera's position as a fully integrated midstream company with greater efficiency and flexibility, enabling us to deliver more value to our customers," said Dean Setoguchi, President and Chief Executive Officer. "With enhanced connectivity and identified synergies, we are positioned to drive industry-leading growth while maintaining the disciplined capital allocation that is expected to create long-term value for shareholders." Delivering Industry Leading Fee-Based Adjusted EBITDA Per Share 1 Growth to 2029 Keyera is establishing pro-forma fee-based adjusted EBITDA per share 1 growth targets to 2029. This growth is highly visible, and supported by sanctioned projects, identified synergies and capital-efficient growth initiatives that are already underway and aligned with the company's strategy. The outlook is further supported by strong basin fundamentals. Oil, natural gas and NGL production across the Western Canadian Sedimentary Basin are expected to continue growing as export market access expands and global demand for Canadian energy products increases. From 2025 to 2027, Keyera expects fee-based adjusted EBITDA per share 1 to increase by approximately 35% or an approximate 16% Compound Annual Growth Rate (CAGR), mainly r

The Vanguard Long-Term Treasury ETF (VGLT) emerges as the more attractive option compared to the iShares 20+ Year Treasury Bond ETF (TLT) for long-term investors, primarily due to its significantly lower expense ratio of 0.03% versus TLT's 0.15%. While both funds offer similar dividend yields around 4.6%, VGLT has delivered better performance with higher 12-month returns and lower volatility, making it the more cost-efficient choice for buy-and-hold investors.

A securities class action lawsuit has been filed against Globant S.A. for allegedly making false and misleading statements about its Latin American operations. The company disclosed significant failures on August 14, 2025, announcing a 2% headcount reduction (1,000 employees) and a $47.6 million restructuring charge, causing the stock to drop from $78.12 to $66.46 per share in a single day. Investors who purchased GLOB stock between February 15, 2024 and August 14, 2025 may be eligible to participate in the class action, with a June 23, 2026 deadline to seek lead plaintiff appointment.

A securities fraud class action lawsuit has been filed against Globant S.A., alleging that the company failed to disclose decreasing demand in Latin America, wage freezes in Argentina and Mexico, and client project cancellations between February 2024 and August 2025. Investors who suffered losses can participate as lead plaintiffs by June 23, 2026.

GLB Intelligent Power Technologies, an automotive electronics and power systems provider, has filed for a Hong Kong IPO. The company has experienced explosive growth driven primarily by its relationship with Geely, with Geely-related revenue accounting for 87.2% of total turnover in 2025. While the power-domain solutions market is projected to grow significantly, GLB faces risks from overreliance on Geely and competition from established suppliers with more diversified customer bases.

Rosen Law Firm is soliciting investors who purchased Globant S.A. (NYSE: GLOB) stock between February 15, 2024 and August 14, 2025 to join a securities class action lawsuit. The lawsuit alleges that Globant misrepresented the success of its $1 billion Latin American strategic pivot, while the company actually faced declining demand, client defections, project cancellations, and employee wage freezes in the region. The lead plaintiff deadline is June 23, 2026.

The Schall Law Firm is seeking investors who purchased Globant S.A. securities between February 15, 2024 and August 14, 2025 to join a class action lawsuit alleging securities fraud. The complaint claims Globant made false and misleading statements about its 'Latin American pivot' strategy, which failed due to declined demand and project cancellations, while simultaneously freezing wages in Latin American countries that impacted employee morale and client service.

The DJS Law Group has filed a class action lawsuit against Globant S.A. (NYSE: GLOB) for securities law violations under the Securities Exchange Act of 1934. The lawsuit alleges that Globant made false and misleading statements regarding its 'Latin American pivot' strategy, which failed to achieve the success the company claimed. The class period spans from February 15, 2024 to August 14, 2025, with a deadline of June 23, 2026 for shareholders to join the case.

Rosen Law Firm has filed class action lawsuits on behalf of investors in GRAIL, Inc. (NASDAQ: GRAL) who purchased stock between May 13, 2025 and February 19, 2026. The lawsuit alleges that GRAIL provided misleading statements regarding its NHS-Galleri trial results, concealing material adverse facts about the trial's ability to demonstrate cancer stage reduction. Investors who purchased during the class period may be eligible for compensation. The deadline to serve as lead plaintiff is August 4, 2026.

Aurion Resources Ltd. has obtained final court approval for its plan of arrangement with Agnico Eagle Mines Limited. Under the deal, Agnico will acquire all outstanding Aurion shares for C$2.60 per share in cash. The arrangement was approved by shareholders and warrantholders on June 5, 2026, and is expected to close on or about June 15, 2026, pending TSX Venture Exchange approval and satisfaction of customary closing conditions.

A class action lawsuit has been filed against Globant S.A. (GLOB) for allegedly making materially false statements about its business operations during the period from February 15, 2024 to August 14, 2025. The company failed to disclose decreasing demand in Latin America, wage freezes, and client project cancellations. The stock declined significantly following three negative announcements in February, May, and August 2025, with cumulative losses exceeding 65%. The deadline to file a lead plaintiff motion is June 23, 2026.

Basel Medical Group Ltd (Nasdaq: BMGL), a Singapore-based medical clinic operator, announced a 1-for-12 reverse stock split effective June 22, 2026, to comply with Nasdaq's minimum bid price requirement of $1 per share. The consolidation will reduce outstanding shares from approximately 18.8 million to 1.6 million shares.

Rosen Law Firm is reminding investors who purchased Graphic Packaging Holding Company securities between February 4, 2025 and February 2, 2026 of the July 6, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges the company made false statements regarding inventory management issues, reduced demand, increased costs, and provided unreliable financial guidance for 2025.

AstraZeneca is advancing its oral GLP-1 receptor agonist elecoglipron into Phase 3 trials after demonstrating significant results in Phase 2b studies. The VISTA trial showed 10.5% weight reduction at 26 weeks, while the SOLSTICE trial achieved 1.9% HbA1c reduction in Type 2 diabetes patients. The drug showed a favorable safety profile with mild gastrointestinal side effects.

AstraZeneca Plc (NASDAQ: AZN ) is advancing its oral GLP-1 receptor agonist, elecoglipron, into an extensive Phase 3 development program after the drug delivered significant weight-loss and diabetes-control results in two Phase 2b studies. The findings , presented at the 2026 Scientific Sessions of the American Diabetes Association and published in The Lancet , support the company's efforts to expand its cardiometabolic, renal, and weight-management portfolio. Elecoglipron is an investigational oral, once-daily, small-molecule GLP-1 receptor agonist that mimics the natural GLP-1 hormone.  VISTA Trial Demonstrates Significant Weight Reduction The VISTA study enrolled 310 adults with obesity or overweight and at least one related comorbidity . Participants receiving elecoglipron 75 mg achieved an average body-weight reduction of 10.5% at 26 weeks, compared with 0.6% for placebo. Weight loss continued through week 36, reaching 11.8% in the treatment group versus 0.3% with placebo. The trial also met its co-primary endpoint measuring the proportion of participants achieving ... Full story available on Benzinga.com

Rosen Law Firm has filed a class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS) on behalf of investors who purchased common stock between April 16, 2025 and May 4, 2026. The lawsuit alleges that GeneDx made false statements regarding the Fabric acquisition's impact on the company's financials and operational efficiencies, while concealing significant viability problems that negatively affected the business. Investors must move the court by August 3, 2026 to serve as lead plaintiff.

SINGAPORE , June 8, 2026 /PRNewswire/ -- VinFast Auto Ltd. announced its unaudited financial results for the first quarter ended March 31, 2026. In the first quarter of 2026, VinFast ("the Company") delivered 58,577 electric vehicles, representing an increase of 61% from the same period last year. International markets accounted for approximately 8% of total deliveries during the quarter. In Vietnam, VinFast's EV deliveries in the first quarter of 2026 increased by 53% year over year. The Company maintained its position as the number one OEM in the domestic automotive market since September 2024. Southeast Asia and India continue to be key growth markets for VinFast. At the end of the first quarter of 2026, VinFast ranked #1 BEV brand in the Philippines, #4 in India and #8 in Indonesia. The Company also delivered 143,136 units of e-scooters and e-bikes in the first quarter, representing an increase of 219% from the first quarter of 2025. In March alone, VinFast received more than 135,000 e-scooter orders and shipped over 93,000 e-scooters to dealers in Vietnam. VinFast currently holds the leading position in Vietnam's electric motorcycle market and, in March, expanded its share of the overall motorcycle market (including both ... Full story available on Benzinga.com

The article compares two bond ETFs: Vanguard Long-Term Treasury ETF (VGLT) and iShares iBoxx Investment Grade Corporate Bond ETF (LQD). VGLT offers lower fees (0.03% vs 0.14%) and zero credit risk through U.S. Treasuries but higher interest rate sensitivity. LQD provides higher yields and lower volatility but carries corporate credit risk. With credit spreads near historic lows, investors receive minimal compensation for taking on corporate risk, making VGLT more attractive for safety-focused portfolios.

Rosen Law Firm announces a securities class action lawsuit against Regencell Bioscience Holdings Limited for allegedly making false and misleading statements regarding market manipulation vulnerabilities and regulatory risks during the period between October 28, 2024 and October 31, 2025. Investors have until June 23, 2026 to serve as lead plaintiff.

Aurion Resources Ltd. announced that its securityholders approved a special resolution to be acquired by Agnico Eagle Mines Limited for C$2.60 per share in cash. The arrangement received overwhelming approval with 99.94% of votes cast in favor. The deal is anticipated to close on or about June 15, 2026, pending final court approval and TSX Venture Exchange approval.

Weight Watchers expanded its GLP-1 weight-loss medication access by joining Eli Lilly's LillyDirect platform, combining branded medications with clinical support. Meanwhile, Eli Lilly partnered with Ascidian Therapeutics on RNA-based kidney disease treatments with potential deal value reaching $1.9 billion. Eli Lilly shares surged 5.13% to $1,134.08.

Glucose Health, Inc. (GLUC) announced the appointment of Gerry David, former CEO of Celsius Holdings (CELH), as Chairman of its newly formed Strategic Advisory Board. David will support the company's growth and business development initiatives in the functional beverage and dietary fiber markets. His appointment is expected to enhance sales and marketing capabilities as the company positions itself for expansion.

Eli Lilly has overtaken Novo Nordisk as the GLP-1 market leader with its Mounjaro and Zepbound drugs, which accounted for nearly two-thirds of sales in Q1 2026. Recognizing the time-limited nature of patent protection and competitive threats like Novo Nordisk's pill formulation, Eli Lilly is aggressively pursuing acquisitions to diversify its pipeline. The company has already completed 8 deals worth $10 billion upfront in 2026 (potentially $25 billion with earnouts) and signals more dealmaking ahead.

WW International (NASDAQ: WW ) on Thursday said its Weight Watchers platform is now available through Eli Lilly Co.'s (NYSE: LLY ) LillyDirect digital health care platform, expanding access to branded GLP-1 weight-loss medications alongside clinical and behavioral support services. • Eli Lilly stock is surging to new heights today. What’s driving LLY stock higher? Weight Watchers Expands GLP-1 Access Through LillyDirect The addition to LillyDirect aligns with Weight Watchers' strategy to broaden access to GLP-1 treatments through its Med+ program, which provides patient support before, during and after treatment. LillyDirect connects patients with independent care options, pharmacy fulfillment resources, and educational content as demand for GLP-1 medications continues to increase . Weight Watchers said its Med+ offering complements these services with a comprehensive care model designed to support long-term weight management. Ascidian, Eli Lilly Partner On RNA-Based Kidney Disease Therapies Ascidian Therapeutics on Wednesday ... Full story available on Benzinga.com

Rosen Law Firm has filed a class action lawsuit against Calix, Inc. on behalf of investors who purchased securities between January 28, 2026 and April 21, 2026. The lawsuit alleges that Calix made false and misleading statements regarding its profit margins, claiming the company benefited from advanced memory component purchases in Q1 but failed to disclose that supplies were dwindling and the company faced negative margin pressure from rising component costs. Investors who wish to serve as lead plaintiff must file by July 27, 2026.

Rosen Law Firm is encouraging investors with losses exceeding $100K in Regencell Bioscience Holdings Limited, Calix, Inc., and Wise Group plc to join securities class action lawsuits. The firm is seeking lead plaintiffs before the June 23, 2026 deadline. Regencell is accused of making false statements regarding market manipulation vulnerability and regulatory risks.

Alphabet announced plans to raise $80 billion for AI infrastructure through a multi-tiered financing strategy, including a $10 billion private placement to Berkshire Hathaway, $30 billion in public offerings, and a $40 billion at-the-market offering. Jim Cramer criticized the ATM offering structure for potential stock dilution, warning it could turn the stock into a 'real slog,' while short-seller Jim Chanos questioned the necessity given Alphabet's $126 billion cash position.

Sika has appointed Philipp Irniger as Head Construction and member of the executive board effective June 1, 2026, succeeding Ivo Schädler who retires after 30+ years. The company also created a new Chief Digital & Information Officer position, with Jochen Werling taking the role to accelerate digital transformation and the Fast-Forward program.

Rosen Law Firm is reminding investors who purchased Globant S.A. (NYSE: GLOB) stock between February 15, 2024 and August 14, 2025 of the June 23, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Globant misrepresented the success of its $1 billion Latin American strategic pivot, while the company actually faced declining demand, client defections, project cancellations, and employee wage freezes in the region.

Alphabet Inc. (NASDAQ: GOOGL ) (NASDAQ: GOOG ) is looking to raise $80 billion through massive equity offerings to fund its aggressive artificial intelligence (AI) infrastructure push, sparking sharp criticism from prominent Wall Street voices. The $80 Billion Funding Breakdown The Google parent company announced plans to secure the capital through a multi-tiered corporate financing strategy. This includes a high-profile $10 billion private placement to Warren Buffett 's Berkshire Hathaway Inc. (NYSE: BRK ) (NYSE: BRK ) , split evenly between Class A and Class C stock. Alphabet will also launch $30 billion in concurrent public offerings and a massive $40 billion at-the-market (ATM) offering program scheduled for the third quarter. The unprecedented capital raise follows Alphabet boosting its annual capital spending forecast to between $180 billion and $190 billion to meet soaring AI-driven demand. data-variant="card" data-news-mode="manual" > Read Also: Alphabet Stock Offers Exposure To SpaceX, Anthropic Before IPOs: What That Means For Investors Cramer Warns Of ... Full story available on Benzinga.com